1
Clinical Trials associated with ChAdV63.HIVconsv booster vaccine(GlaxoSmithKline)A Randomised Double-blind, Placebo-controlled Phase I/IIa Trial to Investigate the Effect of Depletion of Serum Amyloid P Component (SAP) on the Immune Response to DNA Vaccination in Healthy Male Volunteers
This is a clinical proof-of-concept (PoC) study of DNA vaccination after SAP depletion. The investigators will measure the immune responses to DNA vaccination against HIV-1 in healthy adult male volunteers, comparing a group in whom SAP has been completely depleted at the time of DNA vaccination and a control group vaccinated without SAP depletion.
100 Clinical Results associated with ChAdV63.HIVconsv booster vaccine(GlaxoSmithKline)
100 Translational Medicine associated with ChAdV63.HIVconsv booster vaccine(GlaxoSmithKline)
100 Patents (Medical) associated with ChAdV63.HIVconsv booster vaccine(GlaxoSmithKline)
100 Deals associated with ChAdV63.HIVconsv booster vaccine(GlaxoSmithKline)